cerrar
Tagged with India

Orphan Drugs & Rare Diseases: India
Want to know more about orphan drugs & rare diseases in India? Read on! Prepared in association with Nishith Desai & Associates, a leading law…

Biocon’s New Facility & Expansion in APAC
Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with a new manufacturing facility and an…

Three More Key Issues for Pharma: Regulatory Assertiveness,…
Eurasia Group’s Aditya Bhattacharji tackles three more key geopolitical issues that global pharma needs to be cognizant of: the world’s leading…

Key Regulatory Developments in Indian Medtech 2019
Regulation of medical devices in India has speedily evolved in the preceding two years. Before the introduction of the Medical Device Rules, 2017…

India: Key Pricing & Reimbursement Developments in 2019
2019 so far has witnessed a lot of activity in the pharma space, so much so that the e-pharmacy saga – a pressing development towards the close of…

India: Key Healthcare Developments in 2019
The Indian Government has had a busy 2019 so far with respect to healthcare regulation. From passing the controversial National Medical Commission…

Gujarat: The Home of Indian Pharma
The state of Gujarat proudly stands as India’s main pharmaceutical hub, accounting for over 33 percent of the country’s pharmaceutical turnover…

Three Key Political Issues for Pharma: Protests, Pricing &…
This month, Aditya Bhattacharji takes stock of three political issues that are dominating Eurasia Group’s conversations with pharmaceutical firms:…

Pharma Faces: Vivek Sharma, PPS
Unlike many of his pharma peers, Vivek Sharma worked in operations and finance for two decades before joining the life sciences industry as head of…

China: Indian Pharma Firms Incoming
The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports to developed nations, are…

India Healthcare: “Modicare” Lives On
Aditya Bhattacharji is Healthcare Practice Head at Eurasia Group. In this article, he looks at India's ambitious healthcare insurance scheme,…

How Beneficial Is The Recent Price Control Exemption For…
Anay Shukla leads the pharmaceutical, life sciences, med-tech and healthcare practice at Nishith Desai Associates, a leading Indian law firm. In this…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here